[Hyperprolactinemia as a marker of the progression of cervical cancer].
Elevated blood prolactin level was identified in 80% of untreated patients with advanced (stage II-IV) cervical cancer whereas it was normal at the earlier (preinvasive) stage. Patients with stage I-A, II tumors revealed either increased or normal blood prolactin level. Patients with advanced cancer who had undergone irradiation and surgery, either alone or in combination, showed hyperprolactinemia as often as 94% of the time. Studies on pathogenesis of hyperprolactinemia and its role in tumor progression are currently conducted by the authors.
Strukov
E L
EL
Safronnikova
N R
NR
Bobrov
Iu F
IuF
Gamaiunova
V B
VB
Bokhman
Ia V
IaV
Dil'man
V M
VM
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002850:Chromatography, Gel; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000628:therapy; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011388:Prolactin / Q000097:blood; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy
D015415:Biomarkers; D011388:Prolactin
Giperprolaktinemiia kak marker progressii raka sheĭki matki.